SHEPHERD Therapeutics and Mayo Clinic Announce Collaboration to Advance Research in Rhabdomyosarcoma Using SHEPHERD's Precision-Oncology Platform, DELVE

BOSTON, Feb. 25, 2021 /PRNewswire/ -- SHEPHERD Therapeutics , a company dedicated to catalyzing lifesaving treatments for rare cancer patients, today announced a collaboration with the Mayo Clinic to advance research in rhabdomyosarcoma (RMS), a rare pediatric cancer with few treatment options.